Table 1.
Demographic, laboratory and clinical data.
| Patient 1 | Patient 2 | Patient 3 | |
|---|---|---|---|
| Age (years) | 85 | 71 | 80 |
| Gender | M | M | M |
| HTN | Yes | Yes | Yes |
| DM | No | No | No |
| DL | No | No | No |
| Ischaemic cardiopathy | No | No | No |
| Peripheral arteriopathy | Yes | No | Yes |
| Prior CVA | Yes | No | No |
| Atrial fibrillation | No | No | No |
| Artificial valve | No | No | No |
| Prior anticoagulation | No | No | No |
| Prior kidney transplant | No | No | No |
| Time on renal replacement therapy (years) | 5.3 | 4.4 | 4.4 |
| Renal replacement therapy type | HD | HD | PD |
| Venous access | AVF | Permanent catheter | N/A |
| EPO (IU/week) | 2000 | 15,000 | 6000 |
| ASA | Yes | Yes | Yes |
| Pneumonia | Moderate unilateral | Mild bilateral | Moderate bilateral |
| Days of admission | 9 | 12 | 15 |
| ICU admission | No | No | No |
| Immunomodulatory therapy | Hydroxychloroquine, lopinavir/ritonavir | Hydroxychloroquine, lopinavir/ritonavir | Hydroxychloroquine, lopinavir/ritonavir |
| Duration of immunomodulatory therapy (days) | 9 | 5 + 7 | 5 + 7 |
| Treatment with steroids | No | No | No |
| Prophylactic heparin on admission (mg/24 h) | 20 | 20 | 20 |
| High risk of thrombosis (D-dimer >6 times monitoring level) | No | Yes (day 9) | No |
| Dose of heparin due to high risk of thrombosis (mg/day) | N/A | 60 | N/A |
| Duration of intermediate dose heparin treatment (days) | 0 | 18 | 0 |
| Total heparin treatment duration (days) | 9 | 27 | 25 |
| CRP (mg/l) on admission/maximum (ref. 0.0−0.5) | 87.1/216 | 85.7/116.1 | 15.9/103.4 |
| Ferritin (μg/l) on admission/maximum (ref. 30.0–400.0) | NA | 454/502 | 236/328 |
| LDH (U/l) on admission/maximum (ref. 135−225) | 228/249 | 229/313 | 160/194 |
| Hb (g/dl) on admission (ref. 13.0−17.5) | 12 | 10.9 | 10.8 |
| Platelets (103/μl) on admission (ref. 150−450) | 222 | 130 | 134 |
| Lymphopenia (103/μl) on admission/maximum (ref. 1.00−4.50) | 520/180 | 1007/780 | 1222/760 |
| D-dimer (mg/l) on admission/maximum (ref. <0.5) | 3.2/3.2 | 2.1/5.3 | 1.11/1.11 |
| Fibrinogen (mg/dl) on admission/maximum (ref. 200.0−400.0) | NA | 536/565 | 456/956 |
| Time from onset of symptoms to CVA (days) | 16 | 40 | 31 |
| Time from SARS-CoV-2 diagnosis to CVA (days) | 9 | 38/52 | 30 |
| Time from virus CRP becoming negative to CVA (days) | N/A | 17/31 | 16 |
| Time from end of heparin to CVA (days) | N/A | 15/29 | 5 |
| CVA type | Ischaemic | Ischaemic/ischaemic | Ischaemic |
| Location | M2 branch of left MCA | Right thalamic lacunar/left MCA | Cerebellar vermis |
| Other late signs of COVID-19 | No | No | Exanthema |
| Death | Yes | No | No |
5 + 7: five days of hydroxychloroquine and seven days of lopinavir/ritonavir; ASA: acetylsalicylic acid; AVF: arteriovenous fistula; CRP: C-reactive protein; CVA: cerebrovascular accident; DL: dyslipidaemia; DM: diabetes mellitus; EPO: erythropoietin; HD: haemodialysis; HTN: arterial hypertension; ICU: intensive care unit; LDH: lactate dehydrogenase; MCA: middle cerebral artery; N/A: not applicable; NA: not available; PD: peritoneal dialysis; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.